Haemonetics Operating Expenses 2010-2024 | HAE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Haemonetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Haemonetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$204.2B
Stryker (SYK)	$146.7B
Boston Scientific (BSX)	$132.6B
EssilorLuxottica (ESLOY)	$112.1B
Medtronic (MDT)	$110.6B
Haleon (HLN)	$43.7B
Lonza Group Ag (LZAGY)	$42.2B
GE HealthCare Technologies (GEHC)	$37.7B
ResMed (RMD)	$35.8B
Terumo (TRUMY)	$29.7B
Koninklijke Philips (PHG)	$24.8B
Zimmer Biomet Holdings (ZBH)	$21.9B
Insulet (PODD)	$18.4B
Baxter (BAX)	$17B
Smith & Nephew SNATS (SNN)	$11.1B
BellRing Brands (BRBR)	$10.2B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.3B
TG Therapeutics (TGTX)	$5.5B
Prestige Consumer Healthcare (PBH)	$4.2B
ICU Medical (ICUI)	$4.1B
Perrigo (PRGO)	$3.8B
Envista Holdings (NVST)	$3.7B
Neogen (NEOG)	$3.2B
Agios Pharmaceuticals (AGIO)	$3.2B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.7B
LeMaitre Vascular (LMAT)	$2.4B